Immunomedics wins FDA approval for new drug to treat aggressive form of breast cancer

(By Adam Feuerstein for STAT)

Immunomedics secured U.S. approval on Wednesday for a new drug to treat women with a particularly aggressive type of metastatic breast cancer.

The Food and Drug Administration disclosed the approval of the new drug, called Trodelvy, on its website. The drug’s review had been held up for more than a year due to problems at Immunomedics’ New Jersey manufacturing facility, now resolved.  Continue reading article here..

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.